Barr Reports Third Quarter 2007 GAAP Earnings of $0.36 Per Share; Adjusted Earnings of $0.75...( - Strong Generic and Pr...),Health

- Strong Generic and Proprietary Revenue Growth

- Stable Alliance and Development Revenue

- $20 Million Increase in R&D Investment

WOODCLIFF LAKE, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $38.9 million, or $0.36 per share, for the quarter ended September 30, 2007, compared to net earnings of $52.8 million, or $0.49 per share, for the same period last year. Revenues for the current quarter totaled $601 million, compared to $332 million for the same period last year. Adjusted earnings per share were $0.75 for the third quarter of 2007, compared to adjusted earnings per share of $0.87 in the prior year period. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release.

For the nine months ended September 30, 2007, net earnings were $95.8 million, or $0.88 per share, compared to $211.1 million, or $1.95 per share, in the prior year period. Revenues for the first nine months of 2007 totaled $1.8 billion, compared to $1.0 billion for the same period last year. Adjusted earnings per share were $2.37 for the nine months ended September 30, 2007, compared to adjusted earnings per share of $2.64 in the prior year period.

"Strong performances by our U.S. generic and proprietary businesses drove a sound third quarter," said Bruce L. Downey, Barr's Chairman and Chief Executive Officer. "We delivered $77 million in revenue growth in U.S. generic sales, fueled by the inclusion of PLIVA's product line and sales of Fentanyl Citrate, and $21 million in proprietary revenue growth primarily from sales of our Plan B(R) emergen
'/>"/>